348 related articles for article (PubMed ID: 17644541)
41. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?
Benucci M; Manfredi M; Puttini PS; Atzeni F
Autoimmun Rev; 2010 Oct; 9(12):801-3. PubMed ID: 20656069
[TBL] [Abstract][Full Text] [Related]
42. Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.
Dass S; Vital EM; Emery P
Expert Opin Pharmacother; 2006 Dec; 7(18):2559-70. PubMed ID: 17150009
[TBL] [Abstract][Full Text] [Related]
43. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
44. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
45. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Celis R; Moll C; Izquierdo E; Marsal S; Sanmartí R; Palacín A; Lora D; de la Cruz J; Pablos JL
Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
[TBL] [Abstract][Full Text] [Related]
46. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
[TBL] [Abstract][Full Text] [Related]
47. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: a randomised, placebo controlled, proof-of-concept study.
Boumans MJ; Houbiers JG; Verschueren P; Ishikura H; Westhovens R; Brouwer E; Rojkovich B; Kelly S; den Adel M; Isaacs J; Jacobs H; Gomez-Reino J; Holtkamp GM; Hastings A; Gerlag DM; Tak PP
Ann Rheum Dis; 2012 Feb; 71(2):180-5. PubMed ID: 21917822
[TBL] [Abstract][Full Text] [Related]
48. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
49. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC; Wijbrandts CA; van Baarsen LG; Rustenburg F; Baggen JM; Verweij CL; Tak PP
Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
[TBL] [Abstract][Full Text] [Related]
50. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab).
Buch MH; Reece RJ; Quinn MA; English A; Cunnane G; Henshaw K; Bingham SJ; Bejarano V; Isaacs J; Emery P
Rheumatology (Oxford); 2008 Oct; 47(10):1469-75. PubMed ID: 18660510
[TBL] [Abstract][Full Text] [Related]
51. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study.
Sellam J; Hendel-Chavez H; Rouanet S; Abbed K; Combe B; Le Loët X; Tebib J; Sibilia J; Taoufik Y; Dougados M; Mariette X
Arthritis Rheum; 2011 Apr; 63(4):933-8. PubMed ID: 21225699
[TBL] [Abstract][Full Text] [Related]
52. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
[TBL] [Abstract][Full Text] [Related]
53. Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis.
Thurlings RM; Teng O; Vos K; Gerlag DM; Aarden L; Stapel SO; van Laar JM; Tak PP; Wolbink GJ
Ann Rheum Dis; 2010 Feb; 69(2):409-12. PubMed ID: 19596693
[TBL] [Abstract][Full Text] [Related]
54. Improvement of refractory rheumatoid arthritis after depletion of B cells.
Kneitz C; Wilhelm M; Tony HP
Scand J Rheumatol; 2004; 33(2):82-6. PubMed ID: 15163108
[TBL] [Abstract][Full Text] [Related]
55. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.
van Assen S; Holvast A; Benne CA; Posthumus MD; van Leeuwen MA; Voskuyl AE; Blom M; Risselada AP; de Haan A; Westra J; Kallenberg CG; Bijl M
Arthritis Rheum; 2010 Jan; 62(1):75-81. PubMed ID: 20039396
[TBL] [Abstract][Full Text] [Related]
56. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
Chen DY; Chou SJ; Hsieh TY; Chen YH; Chen HH; Hsieh CW; Lan JL
J Formos Med Assoc; 2009 Apr; 108(4):310-9. PubMed ID: 19369178
[TBL] [Abstract][Full Text] [Related]
57. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
[TBL] [Abstract][Full Text] [Related]
58. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
59. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis.
Visvanathan S; Marini JC; Smolen JS; Clair EW; Pritchard C; Shergy W; Pendley C; Baker D; Bala M; Gathany T; Han J; Wagner C
J Rheumatol; 2007 Jul; 34(7):1465-74. PubMed ID: 17552048
[TBL] [Abstract][Full Text] [Related]
60. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis.
Rosengren S; Wei N; Kalunian KC; Kavanaugh A; Boyle DL
Rheumatology (Oxford); 2011 Mar; 50(3):603-10. PubMed ID: 21098574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
